<p>** The direction of the beneficial effect is in favor of the nonpreferred option. The certainty of evidence is high for the combination of methotrexate plus a TNF inhibitor and moderate for other bDMARDs.</p>

<h1>Table 3. Methotrexate administration*</h1>